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Glutathione disulﬁde (GSSG) is the oxidized form of glutathione (GSH). GSH is a tripeptide present in the
biological system in mM concentration and is the major antioxidant in the body. An increase in GSSG
reﬂects an increase in intracellular oxidative stress and is associated with disease sates. The increase has
also been demonstrated to lead to an increase in protein S-glutathionylation that can affect the structure
and function of proteins. Protein S-glutathionylation serves as a regulatory mechanism during cellular
oxidative stress. Though GSSG is commercially available, its roles in various GSSG-associated normal/
abnormal physiological functions have not been fully delineated due to the reason that GSSG is not cell
membrane permeable and a lack of method to speciﬁcally increase GSSG in cells. We have developed
cationic liposomes that can effectively deliver GSSG into cells. Various concentrations of GSSG liposomes
can be conveniently prepared. At 1 mg/mL, the GSSG liposomes effectively increased intracellular GSSG
by 27.176.9 folds (n¼3) in 4 h and led to a signiﬁcant increase in protein S-glutathionylation conﬁrming
that the increased GSSG is functionally effective. The Trypan blue assay demonstrated that GSSG lipo-
somes were not cytotoxic; the cell viability was greater than 95% after cells were treated with the GSSG
liposomes for 4 h. A stability study showed that the dry form of the GSSG liposomes were stable for at
least 70 days when stored at 80 °C. Our data demonstrate that the GSSG liposomes can be a valuable
tool in studying GSSG-associated physiological/pathological functions.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glutathione disulﬁde (GSSG) is the oxidized form of glu-
tathione (GSH). GSH is an endogenous three amino acid peptide
present in mM concentration in cells and serves as the major an-
tioxidant in the biological system [1]. GSH protects the biological
system from oxidizing factors such as reactive oxygen species
(ROS) or reactive nitrogen species (RNS) through terminating them
while GSH itself is oxidized to GSSG. GSSG is then reduced back to
GSH by glutathione reductase (GR) to maintain thiol redox
homeostasis (Fig. 1). Under normal conditions, the biological sys-
tem maintains a high ratio of GSH:GSSG (4100:1) through ef-
fective reduction of GSSG back to GSH. An increase in GSSG is
considered as an increase in cellular oxidative stress [2].an open access article under the C
H, glutathione; DDAB, di-
te buffered saline; FBS, fetal
ty, College of Pharmacy, Box
Guan).An increase in GSSG has also been implicated in various diseases
such as neurodegenerative diseases [3] and cystic ﬁbrosis [4]. Fur-
ther, an increase in GSSG was demonstrated to increase protein S-
glutathionylation [5]. Protein S-glutathionylation is involved in oxi-
dative stress and structural and functional modiﬁcation of proteins.
Protein S-glutathionylation also serves as a cellular regulatory me-
chanism like protein phosphorylation [5]. A study of the effects of
GSSG changes on GSSG-associated physiological/pathological states
and protein S-glutathionylation remains challenging due to a lack of
a research tool to speciﬁcally increase intracellular GSSG levels since
GSSG is a cell membrane impermeable molecule. Current methods
to increase intracellular GSSG levels mainly include a microinjection
approach [6] and use of GSSG methyl ester [7]; the latter is expected
to be hydrolyzed to yield GSSG intracellularly. The microinjection
approach requires an expertize and is not applicable for most in vitro
and in vivo studies. The obvious drawback of GSSG methyl ester is
that the rate of hydrolysis by esterases may not be the same in
different cells. Also, GSSG methyl ester is not suitable for in vivo
study since it will be quickly hydrolyzed in plasma before it can
reach the targeted site.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of GSSG and its relationship with intracellular antioxidant GSH.
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through the use of a GR inhibitor [8]. However, the inhibitor was
later found also to inhibit other disulﬁde reductases such as glu-
taredoxin [9] and thioredoxin reductase [10]. Therefore, the in-
hibitor is more appropriate as a tool to block all disulﬁde reduction
to increase cellular thiol oxidative stress but not selective enough
for the study of the impact caused by GSSG alone.
Here we would like to report a method that effectively delivers
GSSG into cells through the use of cationic liposomes. The increase
of GSSG led to a signiﬁcant increase in cellular protein S-glu-
tathionylation conﬁrming that the delivered GSSG is functionally
effective. This is the ﬁrst method that delivers speciﬁcally GSSG,
not in the other forms of GSSG such as GSSG methyl ester, into
cells. The method will be valuable in studying the impact of GSSG
on GSSG-associated cellular function/dysfunction and provide
unambiguous information regarding the roles of GSSG in these
function/dysfunction. Similarly, it will be valuable in studying
protein S-glutathionylation-related function/dysfunction.1 GSSG liposomes for cell culture use were prepared by reconstituting the
stored freeze-dried liposomes with sterile water instead of deionized water.
2 1 mg of GSSG and 1 mg of lipid.2. Material and methods
2.1. Materials
Lecithin (Phospholipon 90 G) was obtained as a gift from Lipoid
(Ludwigshafen, Germany). Cholesterol was supplied by MP Bio-
medicals (Solon, Ohio), dimethyldioctadecylammonium bromide
(DDAB) and GSSG were obtained from Applichem (Darmstadt,
Germany). GSH was obtained from Sigma-Aldrich Chemical Co. (St.
Louis, MO). Chloroform and LC/MS grade acetonitrile, water and
formic acid were obtained from Fisher Scientiﬁc (Fair Lawn, NJ).
5-Sulfosalicylic acid was purchased from J.T. Baker Chemical Co.
(Phillipsburg, NJ). RPMI 1640 growth medium, penicillin/strepto-
mycin, phosphate buffered saline (PBS), and trypsin were obtained
from Mediatech (Herndon, VA). Fetal bovine serum (FBS) was
purchased from Atlanta Biologicals (Lawrenceville, GA). NCI-H226
cells (human non-small cell lung carcinoma) were obtained from
the National Cancer Institute.
2.2. Preparation of GSSG cationic liposomes
The GSSG liposomes were prepared using a dehydration/rehy-
dration method with minor modiﬁcation [11]. Brieﬂy, Lecithin
(70 mg), cholesterol (10 mg) and DDAB (20 mg) were dissolved in
chloroform (10 mL), and evaporated to dryness to form a thin and
homogeneous lipid ﬁlm by rotation in a 250 mL round bottom ﬂask
under a reduced pressure at 40 °C. The lipid ﬁlm was then hydrated
with a GSSG PBS loading solution (GSSG dissolved in PBS) (10 mL).
Size reduction of the resulting suspension was performed by soni-
cation in a bath sonicator at 40 °C (4 min sonication with 1 min
break) for 20 min. After sonication the resulting liposomal suspen-
sion was distributed in aliquots of 1 mL each and frozen at 80 °C
for 12 h, freeze-dried, and stored at 80 °C for later use.
To use the stored freeze-dried GSSG liposomes, the liposomes
in the vial were reconstituted in water (1 mL) (rehydration), vortex
mixed for 1 min, and allowed to stand at 40 °C for 10 min, then at
room temperature for additional 20 min. The reconstitutedliposomes were loaded to a Sephadex column (PD10 Columns, GE
Health care, Little Chalfont, UK) and centrifuged to yield the GSSG
liposomes. GSSG liposomes were prepared with equal amount of
GSSG and lipid in the liposome formulation: GSSG liposomes at
1 mg/mL mean the liposome formulation contained 1 mg GSSG
and 1 mg lipid.
2.3. Determination of particle size and zeta potential
The above rehydrated liposomes were further subjected to a di-
lution of 1:100 with deionized water and then examined for particle
size and zeta potential by photon correlation spectroscopy and Dop-
pler anemometry using Malvern Zeta One Zeta Potential/Particle Sizer.
2.4. Determination of GSSG loading
The liposome samples prepared above were diluted further using
3% sulfosalicylic acid (1:10 dilution) and sonicated for 1 h. This so-
nicated sample was further diluted in 0.1% triﬂuoroacetic acid (1:100
dilution). The resulting solution was centrifuged at 14,000 rpm for
3 min before analysis using LC/MS/MS. LC/MS/MS quantiﬁcation of
GSSG employed an Agilent Eclipse XDB-C18 column (1.0150 mm,
3.5 mm) equipped with an Agilent ZORBAX Eclipse XDB guard col-
umn (1.017 mm, 5 mm). The mobile phase was composed of 0.1%
formic acid and acetonitrile at a ratio of 92/8 (v/v). The ﬂow rate was
set at 70 mL/min. In MS/MS detection, the electrospray ion source
was operated in the positive ionization mode with the following
optimized parameters: sheath gas 85 arb, spray voltage 4.5 kV, ca-
pillary temperature 350 °C, capillary voltage 3 V and tube lens offset
60 V. Selected reaction monitoring (SRM) was performed to
monitor the mass transition of 613-484 (GSSG). Under these con-
ditions, the retention time of GSSG was 3.0 min. The injection vo-
lume was 1 mL. GSSG was quantiﬁed based on a GSSG standard curve
constructed right after the GSSG sample analysis.
2.5. Stability of the stored freeze-dried GSSG liposomes
The GSSG liposomes prepared above were distributed 1 mL
each in a 1 mL centrifuge vial, frozen at 80 °C, freeze-dried, and
then stored at 80 °C. Periodically, vials containing the freeze-
dried GSSG liposomes were reconstituted with water (1 mL),
passed through a Sephadex column to remove nonencapsulated
GSSG, and analyzed for the encapsulated liposomal GSSG by LC/
MS/MS as described above. The stability of the stored freeze-dried
GSSG liposomes was determined over a period of 70 days.
2.6. Cellular uptake of GSSG liposomes in NCI-H226 cells
Exponentially growing NCI-H226 cells (4106) were placed in
a 75 cm2 ﬂask in RPMI 1640 growth medium containing 10% FBS
and 1% penicillin/streptomycin in a 5% CO2 incubator at 37 °C for
12 h for attachment before treated with GSSG liposomes1
















GSSG loading solution (mg/mL in PBS)
Fig. 2. A plot of encapsulated GSSG in liposomes against the concentration of GSSG
in GSSG loading solution used to prepare the GSSG liposomes. GSSG loading so-
lution (GSSG in PBS, 10 mL) was used to wet the lipid layer to prepare crude GSSG
liposomes through soniﬁcation, dehydration/hydration as described in the experi-
mental procedure part. The crude GSSG liposomes then passed a Sephadex column
to remove nonencapsulated GSSG. The quantity of GSSG in the liposomes was
determined by an LC/MS/MS method. The results are presented as mean7SD of
independent triplicate experiments.
S.S. Sadhu et al. / Biochemistry and Biophysics Reports 7 (2016) 225–229 227treatment, the medium was removed, and the cells were rinsed
with PBS thrice and detached by trypsinization. The cell suspen-
sion was centrifuged at 1000 g for 5 min. The cell pellet was wa-
shed with 1 mL ice-cold PBS containing 1 mM EDTA and re-
suspended in 0.5 mL of ice-cold 5-sulfosalicylic acid (3%, w/v).
Cells were then disrupted by an ultrasonic processor (Qsonica
sonicators) with a cup horn probe for 5 min and centrifuged at
20,817 g for 3 min at 4 °C. Protein content was determined using
a BCA protein assay method [12]. Quantiﬁcation of GSSG was
achieved by LC/MS/MS as described above using a calibration
curve constructed from samples of GSSG prepared by spiking
known amounts of GSSG standard solution to pooled cell lysates
and diluted with 0.1% formic acid. Three controls (medium alone,
aqueous GSSG, and liposomes without GSSG) were conducted in
parallel.
2.7. Cell viability determination
Cell viability of NCI-H226 cells treated with GSSG liposomes
was determined by the Trypan blue assay according to the man-
ufacture instruction (Sigma).
2.8. Protein S-glutathionylation
Protein S-glutathionylation was determined based on a re-
ported procedure with minor modiﬁcation [13]. Brieﬂy, ex-
ponentially growing NCI-H226 cells (6 million) were plated in a
medium ﬂask (75 cm2) and placed in an incubator overnight, and
the cells were subjected to GSSG liposomes treatment (1 mg/mL)
and incubated for 4 h at 37 °C in an incubator containing 5% CO2.
The cells were processed and subjected for determination of pro-
tein S-glutathionylation by HPLC as outlined in the literature [13].
Three controls (medium alone, aqueous GSSG, and liposomes
without GSSG) were conducted in parallel.Fig. 3. Stability study of dry GSSG liposomes stored at 80 °C. The freeze-dried
GSSG liposomes were reconstituted with water, passed through a Sephadex column
to remove nonencapsulated GSSG, and analyzed for the encapsulated GSSG by LC/
MS/MS. The results are from one of the duplicate experiments.3. Results
3.1. GSSG cationic liposomes
GSSG cationic liposomes were prepared based on a dehydra-
tion/rehydration method with minor modiﬁcation. GSSG en-
capsulation in liposomes was quantiﬁed by an LC/MS/MS method.
A study of GSSG encapsulation in liposomes vs GSSG concentration
in the GSSG loading solution was conducted. Fig. 2 demonstrated
that encapsulated GSSG increased with GSSG concentration in the
GSSG PBS loading solution. The increase reached to a maximum
when GSSG was increased to 100 mg/mL. Further increase in GSSG
concentration did not increase GSSG encapsulation in the lipo-
somes. Accordingly, GSSG liposomes prepared with 100 mg/mL
GSSG loading solution were used for the rest of the study. The size
and zeta potential of the resultant GSSG liposomes were de-
termined to be 190742 nm and 70715 mV respectively
(mean7SD, n¼3).
3.2. Stability of freeze-dried GSSG liposomes
The stability of the stored freeze-dried GSSG liposomes was
determined over a period of 70 days. As demonstrated in Fig. 3, no
signiﬁcant change was noted in GSSG encapsulation in samples
that were stored at 80 °C for 70 days.
3.3. Intracellular delivery of GSSG liposomes
NCI-H226 cells were employed to determine the uptake of
GSSG liposomes by cells. After NCI-H226 cells were treated withGSSG liposomes (1 mg/mL), intracellular GSSG was quantiﬁed by
an LC/MS/MS method. As presented in Fig. 4, intracellular GSSG
increased with time and reached the maximum at 4 h. A max-
imum of 27.176.9 folds (n¼3) increase in intracellular GSSG was
observed. No GSSG increase was observed for all three controls
(medium alone, aqueous GSSG, and liposomes without GSSG). The
cell viability was observed to be 495% for controls and cells
treated with GSSG liposomes at the end of 4 h.3.4. Protein S-glutathionylation
An increase in intracellular GSSG by a GR inhibitor was re-
ported to increase protein S-glutathionylation [13]. To check
whether GSSG delivered to cells by liposomes is functionally ef-
fective, cellular protein S-glutathionylation was determined. When
NCI-H226 cells were treated with GSSG liposomes (1 mg/mL) for
4 h, intracellular GSSG was increased by 20 folds. The treatment
also led to a signiﬁcant increase in protein S-glutathionylation;
protein S-glutathionylation was found to be 1.7270.74 nmol/mil-
lion cells (n¼3) in the treated cells while no protein S-glutathio-
nylation was detected for cells treated with medium alone (con-
trol), aqueous GSSG (1 mg/mL), or liposomes without GSSG. The
results demonstrate that GSSG delivered by liposomes is func-
tionally effective.
Fig. 4. A time course of intracellular GSSG delivered by GSSG liposomes. Ex-
ponentially growing NCI-H226 cells (4106) were treated with GSSG liposomes*
(1 mg /mL)**. Intracellular GSSG was determined by an LC/MS/MS method. The
results are presented as fold increase over the medium control and as mean7SD of
independent triplicate experiments for GSSG liposomes. The data obtained from
medium, aqueous GSSG, and liposomes are presented as one representative of two
independent experiments. *GSSG liposomes for cell culture use were prepared by
reconstituting the stored freeze-dried liposomes with sterile water instead of
deionized water. **1 mg of GSSG and 1 mg of lipid.
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Liposomes consist of an aqueous core surrounded by one or
multiple bilayers composed of natural or synthetic lipids [14–17]. The
lipids are biologically inert and weakly immunogenic with low toxi-
city [14–17]. Liposomes are able to encapsulate compounds with
different lipophilicities with water-soluble compounds entrapped
into aqueous core and lipophilic ones in phospholipid bilayer [14–17].
Liposomes are widely used to aid absorption of cell membrane im-
permeable compounds. Since its discovery by Alec D Bangham in the
1960s at the Babraham Institute, University of Cambridge, liposomes
have been extensively investigated for the delivery of drugs, diag-
nostics, vaccines, nutrients and other bioactive agents and considered
as the most successful drug-carrier system known to date for its ef-
ﬁcient delivery, biodegradability, and biocompatibility [15–19]. De-
pending on the charge on liposomal surface, liposomes can be di-
vided into negatively charged (anionic), positively charged (cationic),
and neutral liposomes [14–17]. Cationic liposomes have been ex-
tensively used in gene delivery due to the electrostatic interaction
with the negatively charged DNA [15–17,20]. Cationic liposomes help
increase the uptake of the entrapped materials through electrostatic
interaction between positively charged liposomes and negatively
charged cell membrane [15–17,21]. In general, the cellular uptake of
liposomes occurs through membrane fusion and receptor-mediated
endocytosis [15–17,22,23]. The cationic lipid DDAB also helps in es-
caping the endolysosomal pathway which would degrade proteins or
peptides to constituent amino acids [24]. Although positively charged
lipids are reported to be cytotoxic, the composition of liposomes
employed in this method was reported to be less toxic [25].
An increase in intracellular GSSG has been associated with
various normal and abnormal cellular functions [3]. A direct out-
come of an increase in intracellular GSSG is protein S-glutathio-
nylation resulted from a thiol-disulﬁde exchange reaction of a
protein thiol with GSSG. Physiologically, protein S-glutathionyla-
tion serves as a mechanism to protect a protein thiol from irre-
versible oxidation during oxidative stress [5]. Protein S-glutathio-
nylation also serve as a cellular regulatory mechanism like protein
phosphorylation [5]. An increase in GSSG has been reported in a
number of disease states such as neurodegenerative diseases. All
neurodegenerative diseases are characterized by progressive loss
of neurons [3]. These diseases confront the growing elderly po-
pulation and have become a major public health issue and eco-
nomic burden due to the need for extensive long-term health care.
A common neuropathological feature of these diseases isassociated with increased oxidative damage to biological macro-
molecules such as proteins, lipids, and nucleic acids in neurode-
generative tissue. Increased levels of GSSG were observed in
postmortem brain samples of patients [3]. Recent studies show
that dysregulation of redox signaling and sulfhydryl homeostasis
likely contributes to onset/progression of neurodegeneration [3].
S-Glutathionylation of key enzymes and proteins has been im-
plicated in neurodegenerative diseases. However, the exact roles of
sulfhydryl homeostasis and protein S-glutathionylation in the pa-
thology of these diseases are not fully understood. This ﬁeld is
evolving and much remains to be explored.
The inability of GSSG to pass through cell membrane and a lack
of effective method to deliver it into cells has hampered our ability
to investigate the role of GSSG in its normal and abnormal cellular
functions. Liposomes as one of the most effective and widely used
delivery systems have been employed to aid the delivery of
bioactive agents through various biological membrane and biolo-
gical barriers including blood-brain barrier (BBB) [26]. GSSG lipo-
somes reported here are the ﬁrst method that delivers speciﬁcally
GSSG into cells. We demonstrated that different concentrations of
GSSG liposomes can be conveniently prepared through the use of a
PBS solution containing different concentrations of GSSG; pro-
viding us the ability to manipulate intracellular GSSG concentra-
tion. The data from protein S-glutathionylation conﬁrmed that
GSSG delivered to cells by GSSG liposomes were functionally ef-
fective. Further, cell viability study showed that GSSG liposomes
exhibited no signiﬁcant cytotoxicity. Therefore, the GSSG lipo-
somes can serve as a valuable tool in studying the role of GSSG in
GSSG-associated cellular function and dysfunction. These studies
can help identify approaches to prevent GSSG-associated diseases
and potentially provide effective treatments. GSSG liposomes can
also undoubtedly help the investigation of the role of protein S-
glutathionylation in various cellular regulatory mechanisms.5. Conclusion
GSSG liposomes reported here provide the ﬁrst method that
delivers GSSG into cells. Since the method delivers only GSSG into
cells, it avoids any complications caused by other indirect way to
increase intracellular GSSG such as the use of a GR inhibitor. The
method provides an unambiguous tool in investigating GSSG-as-
sociated roles in cellular function and dysfunction. The simple
procedure for preparation and storage stability of the dry GSSG
liposomes provides convenience and also makes the product
commercialization possible.Acknowledgment
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